Treatment response to SGLT2 inhibitors : from clinical characteristics to genetic variations

Klen, Jasna (avtor), Dolžan, Vita (avtor)

SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confirmed in clinical trials. However, inter-individual differences in response to treatment with SGLT2 inhibitors may present in everyday clinical practice, and good predictors of glycemic response and the risk for adverse events in an individual patient are lacking. As genetic variability of SGLT2 may influence the treatment response, pharmacogenetic information could support the choice of the most beneficial treatment strategy in an individual patient. This review focuses on the clinical and genetic factors that may influence the treatment response to SGLT2 inhibitors in type 2 diabetes patients with comorbid conditions.

• Jezik: Angleški jezik
• Ključne besede: SGLT2 inhibitors, cardiovascular safety, renal safety, genetic polymorphisms
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Datum objave: 01.01.2021
• Leto izida: 2021
• Št. strani: 12 str.
• Številčenje: Vol. 22, iss. 18, art. 9800
• PID: 20.500.12556/RUL-136108
• UDK: 616.379
• ISSN pri članku: 1422-0067
• DOI: 10.3390/ijms22189800
• COBISS.SI-ID: 77487107
• Datum objave v RUL: 13.04.2022

Gradivo je del revije

• Naslov: International journal of molecular sciences
• Skrajšan naslov: Int. j. mol. sci.
• Založnik: MDPI
• ISSN: 1422-0067
• COBISS.SI-ID: 2779162

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 10.09.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: SGLT2 inhibitorji, kardiovaskularna varnost, nefrologija, genetski polimorfizem

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P1-0170
• Naslov: Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P3-0298
• Naslov: Geni, hormonske in osebnostne spremembe pri metabolnih motnjah